Regulators have approved new oral therapies for uncomplicated gonorrhea, adding zoliflodacin (Nuzolvence) and gepotidacin (Blujepa/GSK) to treatment options for Neisseria gonorrhoeae. Regulatory notices and company statements indicate both products received expedited designations during review and will broaden antibiotic choices amid rising resistance. The approvals reflect a policy and clinical priority to diversify gonorrhea therapy beyond existing injectables and older oral agents frequently challenged by resistance. Public health and clinical stakeholders will need to update treatment guidelines and stewardship frameworks to integrate these agents while monitoring real‑world resistance patterns. Clinical context: gonorrhea is a rapidly evolving antimicrobial‑resistance threat; new oral agents with distinct mechanisms provide alternatives for outpatient therapy and for patients for whom injections or current regimens are unsuitable.